Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04905459 · ClinicalTrials.gov registry record
ARDA Software for the Detection of mtmDR
A clinical trial, sponsored by Verily Life Sciences.
- Completed
- Registry status
- 1,012
- Enrollment target
NCT04905459 is a clinical trial that has completed, run by Verily Life Sciences. The registered enrollment target is 1,012 participants.
The verdict
NCT04905459 has completed, sponsored by Verily Life Sciences.
- COMPLETED
- Registry status
- 1,012 participants
- Enrollment target
Study Summary
This is a multicenter, observational study with primary endpoints to determine the sensitivity and specificity of two investigational software devices that detect the presence of more than mild diabetic retinopathy (mtmDR) in healthcare settings.
Interventions
- DIAGNOSTIC_TEST ARDA software application
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,012 participants |
| Start Date | 2021-09-30 |
| Est. Completion | 2022-05-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04905459
The ClinicalTrials.gov registry entry for NCT04905459 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,012 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verily Life Sciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ARDA software application is the first listed.
NCT04905459 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04905459 about?
NCT04905459 is a clinical study titled "ARDA Software for the Detection of mtmDR". This is a multicenter, observational study with primary endpoints to determine the sensitivity and specificity of two investigational software devices that detect the presence of more than mild diabetic retinopathy (mtmDR) in healthcare settings.
What is the current status of trial NCT04905459?
This trial is currently completed. The enrollment target is 1,012 participants. The study started on 2021-09-30. Estimated completion is 2022-05-23.
What interventions are being tested in trial NCT04905459?
The interventions under investigation include: ARDA software application (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04905459?
This trial is sponsored by Verily Life Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.